# Trade Mark Journal No.2025/036 5 September 2025

## UK00004255301 27 August 2025 (5,42)

WHITEHAWK THERAPEUTICS

International priority date claimed: 21 March 2025 (United States of America) (99097308)

Class 5
  Pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations for precision oncology; pharmaceutical preparations for the purpose of molecular profiling of tumors to identify targetable alterations; pharmaceutical preparations, namely, a drug formulation comprising antibody-drug conjugates (ADCs) for use in the field of oncology; pharmaceutical preparations, namely, a drug formulation comprising antibody-drug conjugates (ADCs) for use treating GI cancer, prostate cancer, cancer of the head and neck, endometrial cancer, cervical cancer, breast cancer, pancreatic cancer, central nervous system (CNS) tumors, solid tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
Class 42
  Medical and scientific research in relation to precision oncology; medical and scientific research in relation to antibody-drug conjugates (ADCs) in the field of oncology; medical and scientific research for the purpose of molecular profiling of tumors to identify targetable alterations; medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of drug discovery process development, drug discovery validation, drug discovery qualification, and drug discovery manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation and testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation and testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the field of oncology; pharmaceutical research in relation to GI cancer, prostate cancer, cancer of the head and neck, endometrial cancer, cervical cancer, breast cancer, pancreatic cancer, central nervous system (CNS) tumors, solid tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

Whitehawk Therapeutics, Inc.

Representative: CMS Cameron McKenna Nabarro Olswang LLP